Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05254158 | A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity | PHASE1 | COMPLETED | 24 | — | — | Mar 3, 2022 | Sep 7, 2022 | Nov 7, 2023 | 1 | China |
measured in h·nmol/L
| Arm | Type | Description |
|---|---|---|
| NNC0174 0833 1.8 mg | EXPERIMENTAL | Each participant will receive one single dose of NNC0174 0833 |
| NNC0174 0833 0.9 mg | EXPERIMENTAL | Each participant will receive one single dose of NNC0174 0833 |
| NNC0174 0833 0.3 mg | EXPERIMENTAL | Each participant will receive one single dose of NNC0174 0833 |
| Name | Type | Description |
|---|---|---|
| NNC0174 0833 | DRUG | Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin) |
Key inclusion criteria * Chinese male subject aged 18-55 years (both inclusive) at the time of signing informed consent. * Body mass index (BMI) between 20.0 and 39.9 kg/m\^2 (both inclusive) at screening. * Body weight between 60.0 and 110.0 kg (both inclusive) at screening. Key exclusion criteri...